How are MRNA strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the MRNA strangle priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 67.37%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$664.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a MRNA strangle?

The breakeven for the MRNA strangle priced on this page is roughly $53.36 and $72.64 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The MRNA market-implied 1-standard-deviation expected move in the same options snapshot is approximately 19.31%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current MRNA implied volatility affect this strangle?

MRNA ATM IV is at 67.37% with IV rank near 28.86%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

MRNA Strangle Strategy

MRNA (Moderna, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A.

MRNA (Moderna, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $25.12B, a beta of 0.90 versus the broader market, a 52-week range of 22.28-85.6, average daily share volume of 7.1M, a public-listing history dating back to 2018, approximately 5K full-time employees. These structural characteristics shape how MRNA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.90 places MRNA roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a strangle on MRNA?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

MRNA snapshot

As of August 14, 2026, spot at $63.12, ATM IV 67.37%, IV rank 28.86%, expected move 19.31%. The strangle on MRNA below is built from the August 14, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.

Why this strangle structure on MRNA specifically: MRNA IV at 67.37% is on the cheap side of its 1-year range, which favors premium-buying structures like a MRNA strangle, with a market-implied 1-standard-deviation move of approximately 19.31% (roughly $12.19 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated MRNA expiries trade a higher absolute premium for lower per-day decay. Position sizing on MRNA should anchor to the underlying notional of $63.12 per share and to the trader's directional view on MRNA stock.

MRNA strangle setup

The MRNA strangle below is built from the August 14, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With MRNA at $63.12 on that close, the first option leg uses a $66.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed MRNA chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 MRNA shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$66.00	$3.55
Buy 1	Put	$60.00	$3.09

MRNA strangle risk and reward

Net Premium / Debit: -$664.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$664.00
Breakeven(s): $53.36, $72.64
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

MRNA strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on MRNA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$5,335.00
$13.97	-77.9%	+$3,939.49
$27.92	-55.8%	+$2,543.98
$41.88	-33.7%	+$1,148.48
$55.83	-11.5%	-$247.03
$69.79	+10.6%	-$285.46
$83.74	+32.7%	+$1,110.05
$97.70	+54.8%	+$2,505.55
$111.65	+76.9%	+$3,901.06
$125.61	+99.0%	+$5,296.57

When traders use strangle on MRNA

Strangles on MRNA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the MRNA chain.

MRNA thesis for this strangle

The market-implied 1-standard-deviation range for MRNA extends from approximately $50.93 on the downside to $75.31 on the upside. A MRNA long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current MRNA IV rank near 28.86% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on MRNA at 67.37%. As a Healthcare name, MRNA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to MRNA-specific events.

MRNA strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. MRNA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move MRNA alongside the broader basket even when MRNA-specific fundamentals are unchanged. Always rebuild the position from current MRNA chain quotes before placing a trade.

Frequently asked questions

What is a strangle on MRNA?: A strangle on MRNA is the strangle strategy applied to MRNA (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With MRNA stock at $63.12 on the August 14, 2026 close, the strikes shown on this page are snapped to the nearest listed MRNA chain strike and the premiums come straight from that session's bid/ask midpoint.
How are MRNA strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the MRNA strangle priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 67.37%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$664.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a MRNA strangle?: The breakeven for the MRNA strangle priced on this page is roughly $53.36 and $72.64 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The MRNA market-implied 1-standard-deviation expected move in the same options snapshot is approximately 19.31%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on MRNA?: Strangles on MRNA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the MRNA chain.
How does current MRNA implied volatility affect this strangle?: MRNA ATM IV is at 67.37% with IV rank near 28.86%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.